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Abstract  31 
Background: Premature Pre-labor Rupture of Fetal Membranes (PPROM) accounts for 30% 32 
of all premature births and is associated with detrimental long-term infant outcomes. 33 
Premature cervical remodeling, facilitated by matrix metalloproteinases (MMPs), may trigger 34 
rupture at the zone of the fetal membranes overlying the cervix. The similarities and 35 
differences underlying cervical remodeling in PPROM and spontaneous preterm labor with 36 
intact membranes (PTL) are unexplored. Objectives: We aimed a) to perform the first 37 
transcriptomic assessment of the preterm human cervix to identify differences between 38 
PPROM and PTL and b) to compare the enzymatic activities of MMP-2 and 9 between 39 
PPROM and PTL. Study Design: Cervical biopsies were collected following PTL (n=6) and 40 
PPROM (n=5). Biopsies were also collected from reference groups at term labor (TL; n=12) 41 
or term not labor (TNL; n=5). The Illumina HT-12 v4.0 BeadChips microarray was utilized 42 
and a novel network graph approach determined the specificity of changes between PPROM 43 
and PTL. qRT-PCR and Western blotting confirmed the microarray findings. 44 
Immunofluorescence was employed for localization studies and gelatin zymography to assess 45 
MMP activity.  Results: PRAM1, FGD3 and CEACAM3 were significantly higher whereas 46 
NDRG2 lower in the PPROM cervix when compared to the cervix in PTL, TL and TNL. 47 
PRAM1 and CEACAM3 were localized to immune cells at the cervical stroma and NDRG2 48 
and FGD3 were localized to cervical myofibroblasts. The activity of MMP-9 was higher 49 
(1.22±4.403 fold, p<0.05) in the cervix in PPROM compared to PTL. Conclusions: We 50 
identified four novel proteins with a potential role in the regulation of cervical remodeling 51 
leading to PPROM. Our findings contribute to the studies dissecting the mechanisms 52 
underlying PPROM and inspire further investigations towards the development of PPROM 53 
therapeutics.  54 
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Introduction 58 
 59 
Preterm birth (PTB), defined as birth before 37 completed weeks of gestation, remains the 60 
major cause of neonatal morbidity and mortality affecting approximately 1 million 61 
pregnancies each year 1. PTBs are predominantly spontaneous in nature and only 25% are 62 
iatrogenic 2. Spontaneous PTBs (sPTBs) can be the outcome of spontaneous preterm labor 63 
with intact membranes (PTL; 45% of all sPTBs) or preterm pre-labor rupture of membranes 64 
(PPROM; 30% of all sPTBs) 2. Although PTL is likely to follow PPROM, PTL and PPROM 65 
can present as separate entities due to differences in their initiating triggers and the 66 
underlying pathways leading to premature cervical remodeling 3.  67 
 68 
The pathophysiology of PPROM has been poorly explored. It is believed that the tensile 69 
strength of the fetal membranes can be reduced by premature cervical dilation, which can 70 
expose the weakest zone of the fetal membranes to vaginal microorganisms and reduce the 71 
underlying tissue support 4. Indeed, microbial invasion of the amniotic cavity (MIAC) is 72 
present in approximately 30–40% of patients with PPROM 5. It is noteworthy that premature 73 
cervical remodeling in the absence of infection can also result in unscheduled rupture of fetal 74 
membranes. What triggers these cervical changes in the absence of infection and how these 75 
fine-tune the timing of rupture is currently unknown. Genetic factors have been proposed to 76 
predispose women to PPROM and a recent systematic review 6 reported that specific 77 
polymorphisms were associated with PPROM in blood 7-9, amnion 10, 11 and buccal swabs 12, 78 
13
. From these a main regulation axis for PPROM was proposed consisting of pathways 79 
regulating hematologic/coagulation function disorder, local inflammation, collagen 80 
metabolism and matrix degradation. Notably, pregnant women with Ehlers-Danlos syndrome, 81 
an inherited connective tissue disorder resulting from mutations in genes responsible for 82 
collagen structure and/or synthesis, have increased risk for PPROM 14, 15. A proteomic study 83 
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of the human placenta additionally demonstrated an association of PPROM with alterations 84 
in structural/cytoskeletal components of cells and impaired regulation of energy metabolism 85 
and oxidative stress 16. 86 
 87 
In light of the detrimental impact of PPROM on long-term infant outcomes 17, the early and 88 
accurate prediction of the condition could allow for timely intervention in order to improve 89 
perinatal outcomes and reduce obstetric complications, such as chorioamnionitis, neonatal 90 
sepsis or cord prolapse. Assessment of the cervical length and detection of biomarkers in 91 
biological fluids of symptomatic women serves to confirm suspected cases of PTL and 92 
MIAC-associated PPROM 18, 19 but a test which predicts PPROM before it occurs is yet to be 93 
developed.  94 
 95 
Understanding the differences and similarities in the underlying pathologies associated with 96 
PPROM and PTL will allow new avenues for research and treatment. Herein we 97 
hypothesized that different cervical remodeling events facilitate PPROM and PTL. We set 98 
out to explore whether these different events would manifest as a PPROM-specific gene 99 
signature. To our knowledge this is the first genome-wide approach study utilizing human 100 
cervical biopsies to study PPROM and PTL as individual groups.  101 
 102 
Materials and Methods 103 
 104 
Human cervical biopsies  105 
Cervical biopsies were collected at the Karolinska Hospital during 2006-2008 following the 106 
informed consent and approval of the local Ethics Committee. Biopsies were taken directly 107 
(within 30 minutes) after vaginal delivery or caesarean section (CS) transvaginally (at 12 108 
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o’clock position) from anterior cervical lip with scissors and tweezers. A total of 28 women 109 
were recruited: 6 undergoing spontaneous preterm labor (PTL), 5 with preterm premature 110 
rupture of membranes (PPROM) followed by labor, 12 undergoing normal term labor (TL) 111 
and 5 who delivered at term prior to the onset of labor (TNL). Preterm delivery was defined 112 
as delivery before the 37th week of gestation. Women in the PTL, PPPROM and TL groups 113 
were in active labor and demonstrated a ripe cervix, with dilatation of more than 4 cm. All 114 
except two of these subjects delivered vaginally. One woman in the PTL group delivered by 115 
emergency CS due to breech presentation and one in the TL group due to protracted labor. 116 
PPROM was defined as a rupture of membranes at least one hour before onset of contractions 117 
2
. TNL samples were obtained from women undergoing planned CS with unripe cervix. None 118 
of the subjects had clinical signs of infection or chorioamnionitis nor suffered from pre-119 
eclampsia, diabetes or other systemic disease. There were no significant differences between 120 
the groups of pregnant women with respect to maternal age, parity or previous preterm births. 121 
For clinical data of the recruited subjects consult Table 1 Supplemental.  122 
 123 
Sample processing  124 
The samples were processed for RNA and protein extraction or fixed as detailed in 125 
Supplemental Material and Methods 1.  126 
 127 
Illumina HT-12 v4.0 BeadChip expression microarray 128 
A total of 23 samples were QC analyzed using the arrayQualityMetrics package in 129 
Bioconductor 21 and no outliers were identified. The samples were split randomly over the 130 
Illumina HT-12 v4.0 BeadChips to minimize any effect of inter-chip variability. The chips 131 
were imaged using a BeadArray Reader and raw data were obtained with Illumina 132 
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BeadStudio software. Raw and processed data are available at www.ebi.ac.uk/arrayexpress/ 133 
under accession number E-MTAB-5354.  134 
Microarray analysis  135 
Fios Genomics Ltd (Bioquarter, Edinburgh, UK) performed the statistical analysis of the 136 
array as described in Supplemental Material and Methods 2.  137 
 138 
Network graph analysis 139 
Normalized expression data generated by microarray analysis were further filtered to include 140 
only the genes up- or down-regulated genes (p<0.05, fold-change = any) in at least at 1 out of 141 
6 comparisons in order to eliminate the noise created by genes with conserved expression. 142 
That final dataset was used as an input for Biolayout Express3D (BLE) analysis software to 143 
create sample-sample and a gene-gene network graphs as previously described 22, 23 and 144 
further detailed in Supplemental Material and Methods 3.  145 
 146 
QRT-PCR 147 
Quantitative RT-PCR (singleplex) was performed to validate the differences identified in the 148 
microarray and BLE analysis. The original samples used in the microarray were used for the 149 
validation, in addition to 5 new TL samples. Details about the assay are available in 150 
Supplemental Material and Methods 4.  151 
 152 
Western blotting and Immunofluorescence  153 
Western blotting and immunofluorescence were used to quantify and localize PRAM1, 154 
FGD3, CEACAM3 and NDRG2 proteins in the cervix as described in Supplemental Material 155 
and Methods 5.  156 
 157 
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Gelatin Zymography 158 
A total of 20 µg protein was loaded onto precast 10% Novex® gelatin-containing gels 159 
(Thermo Scientific, Wilmington, DE, USA) and separated by electrophoresis. Subsequently, 160 
the gels were incubated with Novex® renaturing and Novex® developing buffer according to 161 
manufacturers’ protocol (Thermo Scientific, Wilmington, DE, USA). Staining was then 162 
performed using the Novex® SimplyBlue SafeStain solution until the sites of membrane 163 
degradation by MMP-2 or MMP-9 manifested as bands on the zymographs. Zymography 164 
bands were quantified using Adobe Photoshop’s CS6 histogram function.  165 
 166 
Statistics 167 
Graphpad Prism 6 (La Jolla, CA 92037 USA) was used for the statistical analysis of the qRT-168 
PCR, Western blotting and Zymography data. For qRT-PCR, the thresholds for the gene of 169 
interest (GOI) and actin-β (ACTB) were set in the linear phase of the exponential region of 170 
the amplification curves. The cycle number at which the PCR signal crossed a set threshold 171 
was used to determine relative gene expression. The average comparative cycle threshold 172 
(Ct) values for the GOI and ACTB were used to calculate ∆Ct and the number was 173 
normalized (∆∆Ct) to the PPROM group. ∆∆Ct values were used for statistical analysis and 174 
data were plotted as fold change (2^(-∆∆Ct)). For Western blotting, the intensity of band 175 
fluorescence was analyzed and the readout value for statistical analysis was the raw ratio of 176 
fluorescence intensity value of protein of interest (POI) and α-Tubulin (POI: α-Tubulin). For 177 
zymography, the readout for statistical analysis was the raw pixel number for each band. All 178 
data were initially analyzed for normal distribution using the Kolmogorov-Smirnov test. 179 
Western blotting (raw fluorescence ratio) and qRT-PCR (∆∆Ct) data were analyzed with one-180 
way ANOVA Dunnett’s test to compare each group to PPROM. Zymography data (raw pixel 181 
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number) were analyzed with one-way ANOVA Tukey’s test. Significance was set at p<0.05. 182 
Error bars denote standard error of the mean (SEM).  183 
 184 
Results 185 
 186 
Microarray identified gene expression differences between PPROM and PTL.  187 
A sample-sample network graph followed by Markov Cluster Algorithm (MCLi=19.3) 188 
analysis was generated from normalized microarray data (Figure 1A, B, C) to understand the 189 
relationship between samples at a finer level. The proximity of samples implied similarity in 190 
genetic signature (Figure 1A) and MCL analysis of the samples identified four clusters 191 
(Figure B). When nodes were coloured according to their group status (Figure 1C) it became 192 
evident that all 5 TNL samples belonged to MCL cluster i, where they shared cluster 193 
membership with 2 PTL samples. Additionally, MCL cluster ii contained 5 out of 7 TL 194 
samples, which shared cluster membership with 4 PTL samples. 3 out of 5 PPROM samples 195 
formed their own cluster (MCL cluster iii) and 1 PPROM sample clustered with 2 TL 196 
samples to form MCL cluster iv. One PPROM sample did not cluster with others, suggesting 197 
it did not genetically identify with other samples. Importantly, PPROM and PTL samples did 198 
not share cluster membership and 60% of PPROM samples clustered together suggesting a 199 
distinct genetic signature specific to the PPROM pathology. Indeed, a strict cut-off revealed 200 
that 44 genes were differentially expressed between the PPROM and PTL groups (Figure 201 
1D) out of which 32 were significantly up-regulated and 12 down-regulated (Figure 2A). A 202 
list of these genes is shown in Table 1. A heatmap analysis (Figure 2B) allowed for visual 203 
identification of the genes with a conserved PPROM-specific high or low expression across 204 
all PPROM samples when compared to all other samples (i.e. FGD3, LILRA5, NDRG2, 205 
PRAM1, CD300LF, CEACAM3, PPDPF, RNA28S). Significantly changed genes in the 206 
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PPROM-PTL comparison were analyzed for enrichment of Kyoto Encyclopedia of Genes 207 
and Genomes (KEGG) pathway membership (Table 2) and Gene Ontology (GO) terms 208 
(Table 3). ‘Osteoclast differentiation’ was the only overexpressed KEGG pathway in the 209 
PPROM group, when compared to PTL, with 5 significant genes up-regulated and 19 GO 210 
terms associated with immunity were enriched.  211 
 212 
Pathological gene signature associated with PPROM. 213 
The normalized microarray data for the 30 up- and 9 down- regulated genes in the PPROM-214 
PTL comparison were used as input to generate two gene-gene network graphs, where each 215 
node represented a gene. MCL analysis (MCLi =1.3) was performed to give an unbiased 216 
assessment of how the up- regulated (Figure 3A) and down-regulated genes (Figure 3B) 217 
clustered. We identified 6 MCL clusters for the up- and 3 for the down-regulated genes 218 
(Figure 3C) and the average (mean) gene expression profile for each cluster was examined to 219 
detect a PPROM-specific signature (Figure 3D-L). As with the heatmap, we identified the 220 
clusters with a high or low averaged expression of genes conserved across all PPROM 221 
samples. Analysis of MCL cluster 4 (Figure 3G) and 5 (Figure 3H) revealed that the 222 
averaged expression of genes in MCL cluster 4 (STK4, CEACAM3, FGD3) and MCL cluster 223 
5 (PRAM1, MYO1F) was higher in the PPROM samples when compared with PTL, TL and 224 
TNL samples. MCL cluster interpretation relied on visual observation and no statistics were 225 
applied at that stage. From the down-regulated MCL clusters, MCL 8 showed a low averaged 226 
expression for NDRG2 and ACOT13 in the PPROM samples (Figure 3K). None of the other 227 
clusters suggested trends worthy of further investigation. From the pool of 7 genes identified 228 
(STK4, CEACAM3, FGD3, PRAM1, MYO1F, NDRG2 and ACOT13), statistical significance 229 
between PPROM compared to PTL, TL and TNL was reached for CEACAM3 (Figure 4A), 230 
PRAM1 (Figure 4D), FGD3 (Figure 4G), and NDRG2 (Figure 4J) as reported by traditional 231 
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microarray analysis performed by Fios Genomics, which was further validated with qRT-232 
PCR and Western blotting. Specifically, the mRNA concentration of CEACAM3 (Figure 233 
4B) was 2.17±0.17 fold lower in the PTL group, 1.79±0.12 fold lower in the TL group and 234 
3.97±0.03 fold lower in the TNL group when compared to PPROM. These values for 235 
PRAM1 (Figure 4E) were 2.55±0.17 fold for PTL, 1.85±0.35 fold for TL and 4.8±0.1 fold 236 
for TNL. The concentration of FGD3 mRNA (Figure 4H) was also 3.34±0.11 fold lower in 237 
PTL, 3.29±0.08 fold lower in TL and 2.7±0,18 fold lower in TNL when compared to 238 
PPROM. In contrast, the mRNA of NDRG2 was in lower concentration in the PPROM 239 
cervix when compared to PTL (-4.16±0.57), TL (-3.62±0.63) and TNL (-4.0±0.42) groups 240 
(Figure 4K). These changes were confirmed in the protein level. CEACAM3 (Figure 4C) 241 
and FGD3 (Figure 4I) were significantly higher in the PPROM group when compared to the 242 
other groups. CEACAM3 was 2.57±0.06 fold lower in the PTL cervix, 2.65±0.07 fold lower 243 
in the TL cervix and 2.77±0.07 fold lower in the TNL cervix. These values for FGD3 were 244 
1.88±0.09 for PTL, 2.02±0.18 for TL and 2.58±0.24 for TNL. PRAM1 (Figure 4F) was 245 
significantly higher in PPROM compared to PTL (2.97±0.15) and TL (3.5±0.08) but not 246 
TNL. NDRG2 (Figure 4L) protein was significantly lower in the PPROM group when 247 
compared to PTL (-6.78±0.5) and TL (7.0±0.54) but not TNL group.  248 
 249 
PPROM-specific markers were localized to immune cells and vascular myofibroblasts. 250 
We explored the localization of PRAM1, CEACAM3, FGD3 and NDRG2 within the cervical 251 
tissue. Although the literature suggests that PRAM1 is predominantly expressed in 252 
granulocytes it did not co-localize with the established granulocyte membrane marker 253 
CEACAM3 (Figure 5D). Instead, PRAM1 was localized to the cytoplasm of a subset of 254 
immune CD45 positive cells (Figure 5H) resident in the cervical stroma (Figure 5C, F, I, 255 
M). Notably, all PRAM1 positive cells stained for CD45, suggesting that these are immune 256 
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cells. We confirmed that PRAM1 positive cells were neither macrophages (Figure 5K) nor 257 
neutrophils (Figure 5O). Positive, albeit marginal, NDRG2 staining was evident in the nuclei 258 
of the endocervical epithelial cells (Figure 6C), which were positive for pan-cytokeratin 259 
(Figure 6B). Strong NDRG2 staining (Figure 6G) was detected in the cytoplasm of 260 
endocervical glands (Figure 6F) and myofibroblasts surrounding blood vessels in the 261 
cervical stroma (Figure 6D). A double staining with Von Willebrand factor (vWF), a marker 262 
expressed in the endothelial cells of the vasculature, confirmed the blood vessel status 263 
(Figure 6J). FDG3 was also expressed in the cytoplasm of myofibroblasts (Figure 6P) 264 
surrounding vWF positive blood vessels (Figure 6N). We found that NDRG2 and FGD3 265 
shared the same localization within myofibroblasts (Figure 6T).  266 
 267 
GO terms for PRAM1, CEACAM3, FGD3 and NDRG2. 268 
All GO enriched terms for the PPROM-specific markers can be found in Table 4.  269 
 270 
The activity of Matrix Metalloproteinase 9 (MMP-9) was higher in the PPROM cervix. 271 
Gelatin zymography revealed that the activity of MMP-9 (Figure 7A), but not MMP-2 272 
(Figure 7B), was significantly higher in the PPROM cervix. Specifically, the activity of 273 
MMP-9 was higher 1.22±4.403 fold in PPROM when compared to PTL (p<0.05), 1.25±4.328 274 
fold compared to TL (p<0.05) and 1.57±6.600 fold compared to TNL (p<0.001) (Figure 7A).  275 
 276 
Comment 277 
 278 
This is the first transcriptomic study of the preterm human cervix, which examined PTL and 279 
PPROM as two separate pathologies and compared gene expression in the two groups. 280 
According to a recent systematic review, only 4% of all transcriptomic studies in term and 281 
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preterm human pregnancies have utilized cervical tissue and, strikingly, none of these has 282 
examined PPROM individually 24. Several genetic polymorphisms associated with PPROM 283 
have been identified in the placenta, membranes and maternal/fetal blood [reviewed in 6] and 284 
smaller-scale studies also demonstrated the presence of PPROM-associated inflammatory 285 
markers in the amniotic fluid 25, 26, fetal membranes 27-29 and maternal serum 30. All these 286 
studies combined with recent proteomic 16 and epigenetic 31 reports of a PPROM signature in 287 
the placenta and maternal blood have established the hypothesis that PPROM and PTL may 288 
have distinct underlying pathologies. It remained to be deduced whether a PPROM signature 289 
would be detected in the cervix. We hypothesized that the cervix might initiate rupture of the 290 
fetal membranes at their contact site through PPROM-specific cervical remodeling events. 291 
Our findings support this hypothesis and demonstrate that PPROM is associated with 292 
expression of key proteins, which may facilitate the organization of the cervical extracellular 293 
matrix (ECM) and indirectly accelerate membranes rupture.  294 
 295 
The GO terms for the overexpressed genes in PPROM, when compared to PTL (Table 3), 296 
were predominantly related to immunity, for example ‘immune system processes’, ‘immunity 297 
mediated by myeloid leukocytes’ and ‘immunity mediated by neutrophils’. This is perhaps 298 
not surprising because physiological cervical remodeling is accompanied by infiltration of 299 
leukocyte subpopulations and neutrophils, which work to achieve the rigidity of the cervix 32, 300 
33
. In line with our findings, a study in the mouse cervix proved that the overarching 301 
mechanism underlying cervical remodeling-associated immune cell influx is similar in term 302 
and preterm parturition and only marginal differences occur whereby the mediators and 303 
effector cells involved may differ 34. Our findings provide the first evidence to suggest that 304 
the immunity modulators employed to mediate cervical remodeling may be additionally 305 
different between the preterm subgroups PPROM and PTL. Immune modulators stimulate 306 
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immune and other cells in the cervical stroma to produce cytokines and MMPs to degrade the 307 
ECM as part of the remodeling process 35 4. MMP-2 and MMP-9 are gelatinases both capable 308 
of degrading collagens type I and III, the main constituents of the cervical ECM 36. MMP-2 309 
and MMP-9 concentration is reportedly elevated in the amniotic fluid of PPROM pregnancies 310 
25
. Both MMP-2 and MMP-9 are produced by human cervical fibroblasts 20 and MMP-9 by 311 
vascular fibroblasts 37, 38 and neutrophil granulocytes 39-41. To contribute to the notion that the 312 
facilitators of ECM degradation may differ between PPROM and PTL or TL in the cervix, 313 
we performed an assay to assess MMP-2 and MMP-9 activity. Indeed, the activity of MMP-9 314 
was increased solely in PPROM.  315 
 316 
Out of the 44 differentially expressed genes between the PPROM and PTL groups identified 317 
with traditional array analysis, our network graph analysis followed by validation, brought 318 
forward 4 key proteins that where over- or under- expressed only in the PPROM cervix. 319 
Although these proteins are novel to the parturition field, there is some evidence to support 320 
that they might be involved in the activation of a pathological cascade, which delivers a 321 
“rupture” signal to the weakest zone of fetal membranes overlying the cervix. Specifically, 322 
NDRG2 may be switched off in cervical myofibroblasts to promote the production of MMP-9 323 
and accelerate a PPROM-specific remodeling process. Down-regulation of NDRG2 has been 324 
previously associated with an increase in the gelatinolytic activities of MMP-2 and MMP-9 42 325 
in adenocarcinomic human alveolar basal epithelial cell line and more reports have shown 326 
direct inhibition of MMP-9 activity by NDRG2 43-45. In support of this hypothesis, cathepsin 327 
D (CTSD), which is also down-regulated in PPROM compared to PTL (Table 1) and shares 328 
GO terms with NDRG2 (Table 4), is additionally a negative regulator of MMP-2 and MMP-9 329 
in endometriotic lesions 46. CEACAM3, a membrane granulocyte protein involved in 330 
neutrophil activation 47, 48, and FGD3 may also work together towards enhancement of MMP-331 
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9 activity in PPROM. It is not unlikely that aberrant infiltrating neutrophil-granulocytes 332 
overexpress CEACAM3 to promote their activation and stimulate MMP-9 secretion. In 333 
support of this notion, genes that share GO terms with CEACAM3 (Table 4) have also been 334 
associated with MMP actions. For example, the osteoclast-associated markers OSCAR and 335 
SIRPA and TREM-1 have all been implicated in MMP-9-mediated responses 49-52. 336 
CEACAM3 shares cluster membership with FGD3 (Figure 3C), suggesting similar regulation 337 
in gene expression, which itself may imply similar functions. FGD3 may control MMP-9 338 
activity in the PPROM cervix by promoting filopodia formation on the plasma membranes of 339 
myofibroblasts 53. It is well established that proteins of the same family with FGD3 organize 340 
such formations on plasma membranes to release MMPs and in turn induce degradation of 341 
the surrounding stroma 54, 55. Remarkably, blockade of filopodia formation by flavoinoids has 342 
been shown to decrease the release of MMP-2 in cancer 56. Electron microscopy studies could 343 
help investigate filopodial formations on cells in PPROM. PRAM1, which shared GO terms 344 
with FGD3 (Table 4), is thought to be predominantly expressed in granulocyte-neutrophils 345 
where it acts as an adaptor protein critical for select integrin functions 57. Integrins are 346 
transmembrane receptors that bridge cell-ECM interactions and activate MMPs 58. A 347 
proteolytic role for integrins has been described in the initiation of labor, whereby they 348 
regulate release of MMP-9 in human fetal membranes 59. Although we did not detect PRAM1 349 
in elastase positive neutrophils or in CEACAM3 positive granulocytes (Figure 5), the 350 
likehood of PRAM1 regulating integrin functions in the cytoplasm of an alternative immune 351 
cell population in the cervix deserves addressing.  352 
 353 
Employing a genome-wide approach has identified key genes associated with PPROM, and 354 
provided an insight into a potential mechanism regulating physiological cervical remodeling. 355 
Analysis of the two top clusters of the up-regulated genes in PPROM (Figure 3D, E) 356 
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demonstrated that the genes within these clusters were overexpressed both in PPROM and, 357 
surprisingly, in TL. The first overexpressed cluster contained various genes involved in bone 358 
marrow-derived cell migration (ARHGAP9, FGR, NFE2) and SLC43A2, the gene coding an 359 
essential transporter of Branched Chain Amino Acids (BCAAs). We propose a new 360 
mechanism to contribute to cervical remodeling in TL and PPROM, whereby the increase of 361 
BCAAs in the cervix triggers the recruitment of bone marrow-derived cells in order to 362 
stimulate MMP-induced degradation. Consistent with our hypothesis, MMP-2 and MMP-9 363 
increase in response to exogenous BCAAs in the hippocampus of rats 60 and bone marrow-364 
derived cells have been also shown to secrete MMPs 61-63. A similar mechanism for cervical 365 
remodeling in TL and PPROM involving bone marrow recruited cells can be further 366 
evidenced by KEGG analysis, where ‘Osteoclast differentiation’ pathway is enriched not 367 
only in PPROM-PTL comparison (Table 2) but also in TL-PTL (Table 3 Supplemental). 368 
Osteoclasts are bone marrow-derived cells traditionally involved in the degradation of bone 369 
matrix 64 and have been described to secrete MMP-2 and MMP-9 62, 63. Further work is 370 
required to prove whether bone marrow-derived osteoclasts or osteoclast-like cells mediate 371 
MMPs-induced degradation of ECM as part of physiological cervical remodeling cascade. It 372 
is noteworthy that only 16 genes were differentially expressed between PPROM and TL, in 373 
contrast to 1285 genes in the TNL-TL comparison. The notion that PPROM and TL might 374 
share some similar pathways for cervical remodeling was additionally supported by the 375 
sample-sample network graph (Figure 1C). In that graph PPROM and TL samples belonged 376 
to the same ‘loose’ local structure whereas the TNL samples belong to a separate ‘tight’ 377 
structure.    378 
 379 
Our study could benefit from a larger sample size but human cervical biopsies are extremely 380 
hard to obtain especially in relation to preterm delivery, which explains why so few studies 381 
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are conducted on the human preterm cervix. Moreover, the biopsies were collected 382 
postpartum and thus postpartum repair mechanism might be reflected in our results. 383 
However, it is not practically and ethically possible to obtain cervical biopsies during vaginal 384 
delivery and the material used in our study was collected within 30 minutes after delivery. 385 
Animal research, for example CRISPR experiments could be useful in future studies, to 386 
identify the phenotype associated with knock out or knock in of the genes we suggest are 387 
important.   388 
  389 
In summary, we have, for the first time identified a gene expression signature involved with 390 
PPROM. It is tempting to hypothesize that the PPROM-specific proteins identified herein act 391 
as contributors in a pathway whereby MMP-9 facilitates ECM degradation in the cervix to 392 
signal a ‘rupture’ message to the overlying membranes. Our work supports the growing body 393 
of evidence suggesting that premature labor is a multifactorial disorder with different 394 
pathways involved for PPROM and PTL.  395 
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Tables 613 
 Table 1: List of up and down-regulated genes  614 
 Symbol FC Adj.P.Val 
Up PRAM1 2.094 1.36E-04 
 SIRPA 2.101 1.36E-04 
 CEACAM3 2.412 2.92E-04 
 CD300LF 2.232 1.82E-03 
 LILRA2 2.598 2.42E-03 
 FGD3 2.735 2.42E-03 
 OSCAR 2.168 2.65E-03 
 TREM1 3.826 2.65E-03 
 OSCAR 2.351 2.65E-03 
 STK4 2.023 2.65E-03 
 NUDT11 2.233 3.09E-03 
 LILRA6 2.522 3.09E-03 
 MAMLD1 2.821 3.23E-03 
 ASGR1 2.063 3.42E-03 
 MYO1F 2.004 3.77E-03 
 MMP25 3.117 3.77E-03 
 TMEM71 2.269 4.96E-03 
 CSF3R 4.164 4.96E-03 
 FGR 3.036 6.00E-03 
 PRDM8 2.577 6.00E-03 
 NLRP12 2.211 6.00E-03 
 FGR 2.668 6.00E-03 
 NFE2 4.23 6.29E-03 
 FKBP1A 2.25 6.38E-03 
 SLC43A2 2.067 7.72E-03 
 CLEC5A 2.374 7.87E-03 
 LILRA5 2.781 7.87E-03 
 ARHGAP9 2.107 8.72E-03 
 GK 2.837 9.61E-03 
 CYTH4 2.437 9.66E-03 
  
Down NDRG2 -3.551 7.52E-04 
 PPDPF -5.093 3.09E-03 
 RNU4ATAC -3.67 3.23E-03 
 PKM -3.278 6.00E-03 
 ACOT13 -2.171 6.00E-03 
 CTSD -2.031 6.38E-03 
 RETSAT -2.565 7.00E-03 
 RNA28S5 -11.005 7.87E-03 
 RNA28S5 -6.788 8.72E-03 
               § Footnote Table 1: Adj.P.Val: at the adjusted p-value < 0.01, FC: fold change >= 2 615 
616 
 617 
Table 2: KEGG pathway enrichment analysis of the up and down-regulated genes that 618 
mapped to significant features at adjusted p<0.05. 619 
 620 
  Name of KEGG pathway Pvalue Genes No. Sig. Genes % Sig. Genes 
Up Osteoclast differentiation 4.34E-06 LILRA2, LILRA5, LILRA6, OSCAR, SIRPA 5 4.1 
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Down Pyruvate metabolism 2.03E-02 PKM 1 2.8 
  Retinol metabolism 2.03E-02 RETSAT 1 2.8 
  Type II diabetes mellitus 2.08E-02 PKM 1 2.7 
  Glycolysis / Gluconeogenesis 3.20E-02 PKM 1 1.8 
  Central carbon metabolism in cancer 3.42E-02 PKM 1 1.6 
  Glucagon signaling pathway 4.74E-02 PKM 1 1.2 
621 
622 
623 
Table 3: GO term enrichment analysis of the up and down-regulated genes that mapped to 624 
significant features at adjusted p<0.001  625 
Ontology Name Pvalue Genes No. Sig. Genes % Sig. Genes
Up BP immune system process 3.44E-06 CD300LF, CLEC5A, CSF3R, FGR, FKBP1A, LILRA2, LILRA5, LILRA6, MYO1F, NLRP12, PRAM1, SIRPA, STK4, TREM1 14 0.7
BP defense response 3.38E-04 CLEC5A, CSF3R, FGR, LILRA2, LILRA5, MMP25, MYO1F, NLRP12, TREM1 9 0.8
BP myeloid leukocyte mediated immunity 3.73E-06 FGR, MYO1F, PRAM1, TREM1 4 7.4
BP cytokine secretion 6.77E-05 CLEC5A, FGR, NLRP12, TREM1 4 3.6
BP protein secretion 4.86E-04 CLEC5A, FGR, NLRP12, TREM1 4 2.1
BP leukocyte mediated immunity 6.62E-04 FGR, MYO1F, PRAM1, TREM1 4 2
BP neutrophil mediated immunity 1.07E-05 MYO1F, PRAM1, TREM1 3 13.6
BP leukocyte degranulation 8.96E-05 FGR, MYO1F, PRAM1 3 6.8
BP regulated secretory pathway 1.75E-04 FGR, MYO1F, PRAM1 3 5.5
BP myeloid cell activation involved in immune response 1.75E-04 FGR, MYO1F, PRAM1 3 5.5
BP positive regulation of cytokine secretion 2.50E-04 CLEC5A, FGR, NLRP12 3 4.8
BP positive regulation of protein secretion 7.97E-04 CLEC5A, FGR, NLRP12 3 3.3
BP regulation of cytokine secretion 8.75E-04 CLEC5A, FGR, NLRP12 3 3.2
BP neutrophil degranulation 1.72E-04 MYO1F, PRAM1 2 20
BP neutrophil activation involved in immune response 2.52E-04 MYO1F, PRAM1 2 16.7
BP neutrophil activation 8.72E-04 MYO1F, PRAM1 2 9.1
BP regulation of myeloid leukocyte mediated immunity 9.54E-04 FGR, PRAM1 2 8.7
BP regulation of leukocyte degranulation 9.54E-04 FGR, PRAM1 2 8.7
BP regulation of regulated secretory pathway 9.54E-04 FGR, PRAM1 2 8.7
Down MF pyruvate kinase activity 8.24E-04 PKM 1 50
MF all-trans-retinol 13,14-reductase activity 4.12E-04 RETSAT 1 100626 
 627 
Footnote Table 3: BP: Biological Process, MF: Molecular Function 628 
629 
 630 
Table 4: Report of the GO terms containing the features PRAM1, FGD3, CEACAM3 and 631 
NDRG2 amongst other genes that mapped to significant features at adjusted p<0.01.  632 
 633 
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Gene Ontology Name Pvalue Genes No. Sig. Genes % Sig. Genes
Up PRAM1 BP response to stimulus 1.12E-02 ARHGAP9, ASGR1, CLEC5A, CSF3R, CYTH4, FGD3, FGR, FKBP1A, LILRA2, LILRA5, MMP25, MYO1F, NFE2, NLRP12, PRAM1, SIRPA, STK4, TREM1 18 0.3
BP immune system process 3.44E-06 CD300LF, CLEC5A, CSF3R, FGR, FKBP1A, LILRA2, LILRA5, LILRA6, MYO1F, NLRP12, PRAM1, SIRPA, STK4, TREM1 14 0.7
BP cell communication 2.44E-02 ARHGAP9, ASGR1, CLEC5A, CSF3R, CYTH4, FGD3, FGR, FKBP1A, LILRA2, NFE2, NLRP12, PRAM1, STK4, TREM1 14 0.3
BP immune response 6.07E-03 CLEC5A, FGR, FKBP1A, LILRA5, MYO1F, PRAM1, TREM1 7 0.6
BP secretion by cell 1.64E-03 CLEC5A, FGR, MYO1F, NLRP12, PRAM1, TREM1 6 0.9
BP secretion 3.04E-03 CLEC5A, FGR, MYO1F, NLRP12, PRAM1, TREM1 6 0.8
BP myeloid leukocyte mediated immunity 3.73E-06 FGR, MYO1F, PRAM1, TREM1 4 7.4
BP leukocyte mediated immunity 6.62E-04 FGR, MYO1F, PRAM1, TREM1 4 2
BP regulation of secretion 1.01E-02 CLEC5A, FGR, NLRP12, PRAM1 4 0.9
BP immune effector process 1.74E-02 FGR, MYO1F, PRAM1, TREM1 4 0.8
BP leukocyte activation 2.33E-02 FGR, FKBP1A, MYO1F, PRAM1 4 0.7
BP regulation of immune response 4.03E-02 FGR, FKBP1A, MYO1F, PRAM1 4 0.6
BP neutrophil mediated immunity 1.07E-05 MYO1F, PRAM1, TREM1 3 13.6
BP leukocyte degranulation 8.96E-05 FGR, MYO1F, PRAM1 3 6.8
BP regulated secretory pathway 1.75E-04 FGR, MYO1F, PRAM1 3 5.5
BP myeloid cell activation involved in immune response 1.75E-04 FGR, MYO1F, PRAM1 3 5.5
BP myeloid leukocyte activation 2.02E-03 FGR, MYO1F, PRAM1 3 2.4
BP leukocyte activation involved in immune response 2.95E-03 FGR, MYO1F, PRAM1 3 2.1
BP cell activation involved in immune response 2.95E-03 FGR, MYO1F, PRAM1 3 2.1
BP exocytosis 1.66E-02 FGR, MYO1F, PRAM1 3 1.1
MF lipid binding 4.65E-02 ARHGAP9, CYTH4, PRAM1 3 0.7
BP neutrophil degranulation 1.72E-04 MYO1F, PRAM1 2 20
BP neutrophil activation involved in immune response 2.52E-04 MYO1F, PRAM1 2 16.7
BP neutrophil activation 8.72E-04 MYO1F, PRAM1 2 9.1
BP regulation of myeloid leukocyte mediated immunity 9.54E-04 FGR, PRAM1 2 8.7
BP regulation of leukocyte degranulation 9.54E-04 FGR, PRAM1 2 8.7
BP regulation of regulated secretory pathway 9.54E-04 FGR, PRAM1 2 8.7
BP granulocyte activation 1.04E-03 MYO1F, PRAM1 2 8.3
BP integrin-mediated signaling pathway 1.16E-02 FGR, PRAM1 2 2.4
BP regulation of exocytosis 1.30E-02 FGR, PRAM1 2 2.3
BP regulation of leukocyte mediated immunity 1.80E-02 FGR, PRAM1 2 1.9
BP regulation of neutrophil degranulation 8.01E-03 PRAM1 1 25
BP regulation of neutrophil activation 1.00E-02 PRAM1 1 20
FGD3 BP response to stimulus 1.12E-02 ARHGAP9, ASGR1, CLEC5A, CSF3R, CYTH4, FGD3, FGR, FKBP1A, LILRA2, LILRA5, MMP25, MYO1F, NFE2, NLRP12, PRAM1, SIRPA, STK4, TREM1 18 0.3
BP cell communication 2.44E-02 ARHGAP9, ASGR1, CLEC5A, CSF3R, CYTH4, FGD3, FGR, FKBP1A, LILRA2, NFE2, NLRP12, PRAM1, STK4, TREM1 14 0.3
BP intracellular signal transduction 2.54E-02 ARHGAP9, CYTH4, FGD3, FGR, FKBP1A, NLRP12, STK4, TREM1 8 0.4
BP positive regulation of molecular function 1.45E-02 ARHGAP9, CYTH4, FGD3, FGR, FKBP1A, NLRP12, STK4 7 0.5
BP regulation of phosphate metabolic process 2.58E-02 ARHGAP9, CYTH4, FGD3, FGR, FKBP1A, NLRP12, STK4 7 0.5
BP regulation of phosphorus metabolic process 2.69E-02 ARHGAP9, CYTH4, FGD3, FGR, FKBP1A, NLRP12, STK4 7 0.5
BP positive regulation of catalytic activity 2.40E-02 ARHGAP9, CYTH4, FGD3, FGR, NLRP12, STK4 6 0.5
BP regulation of intracellular signal transduction 3.39E-02 ARHGAP9, CYTH4, FGD3, FGR, FKBP1A, NLRP12 6 0.5
BP regulation of hydrolase activity 4.74E-02 ARHGAP9, CYTH4, FGD3, FKBP1A, NLRP12 5 0.5
BP regulation of small GTPase mediated signal transduction 4.97E-02 ARHGAP9, CYTH4, FGD3 3 0.7
BP positive regulation of GTPase activity 4.71E-02 ARHGAP9, CYTH4, FGD3 3 0.7
BP regulation of cell shape 1.73E-02 FGD3, FGR 2 2
CC ruffle 3.15E-02 FGD3, FGR 2 1.5
MF guanyl-nucleotide exchange factor activity 3.71E-02 CYTH4, FGD3 2 1.2
BP regulation of Cdc42 GTPase activity 3.94E-02 FGD3 1 5
BP regulation of Cdc42 protein signal transduction 4.52E-02 FGD3 1 4.3
CEACAM3 CC membrane part 6.82E-03 ASGR1, CD300LF, CEACAM3, CLEC5A, CSF3R, FGR, FKBP1A, LILRA2, LILRA5, LILRA6, MMP25, OSCAR, SIRPA, SLC43A2, TMEM71, TREM1 16 0.4
CC integral component of membrane 6.91E-03 ASGR1, CD300LF, CEACAM3, CLEC5A, CSF3R, LILRA2, LILRA5, LILRA6, MMP25, OSCAR, SIRPA, SLC43A2, TMEM71, TREM1 14 0.4
CC intrinsic component of membrane 8.61E-03 ASGR1, CD300LF, CEACAM3, CLEC5A, CSF3R, LILRA2, LILRA5, LILRA6, MMP25, OSCAR, SIRPA, SLC43A2, TMEM71, TREM1 14 0.4
Down NDRG2 CC extracellular vesicular exosome 4.17E-03 ACOT13, CTSD, NDRG2, PKM 4 0.2
CC extracellular membrane-bounded organelle 4.17E-03 ACOT13, CTSD, NDRG2, PKM 4 0.2
CC extracellular organelle 4.17E-03 ACOT13, CTSD, NDRG2, PKM 4 0.2
CC membrane-bounded vesicle 9.41E-03 ACOT13, CTSD, NDRG2, PKM 4 0.1
BP regulation of platelet-derived growth factor production 1.45E-03 NDRG2 1 33.3
BP platelet-derived growth factor production 1.45E-03 NDRG2 1 33.3634 
 635 
Footnote Table 4: BP: Biological Process, MF: Molecular Function, CC: Cellular Component 636 
 637 
  638 
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Figure legends  639 
 640 
Figure 1: Sample-sample network graph of all samples used for the microarray and the 641 
comparisons performed between the groups. A 2D representation of sample clustering in a 642 
3D graph. Each node represents a different sample and edges are coloured to reflect the 643 
Pearson correlation that they represent. Red and blue edges denote high correlation and low 644 
correlation respectively. The same graph is coloured by A. no cluster (r=0.91), B. unbiased 645 
MCL cluster number (MCL 19.3) C. group status. D: Table shows all the comparisons 646 
performed between groups and the number of significant array features at adjusted p-value < 647 
0.01 and fold change >= 2. TL = Term Labor (n=7), TNL = Term Non-Labor (n=5), 648 
PTL=Preterm Labor (n=6), PPROM=Preterm Premature Rupture of Membranes (n=5).  649 
 650 
Figure 2: PPROM vs PTL comparison. A. Volcano plot and B. heatmap showing the 30 651 
features significant up-regulated (red dots) and 9 down-regulated (blue dots) at adjusted p-652 
value < 0.01 and fold change >= 2 in the PPROM group compared to PTL group. A heatmap 653 
shows how genes and samples cluster based on similar expression levels. The bars at the top 654 
indicate the sample group (dark green = TNL, dark blue = PTL, light green = TL, light blue = 655 
PPROM). Normalized expression values are indicated on a color scale with red denoting high 656 
expression and blue low expression.  657 
 658 
Figure 3: Probe-probe network cluster analysis. Probe-probe network graph of the up-659 
regulated (A) and down-regulated (B) genes in the PPROM-PTL comparison. Each node 660 
represents a gene and nodes are coloured according to membership of different MCL (MCLi 661 
= 1.3) clusters. C: The genes belonging to each cluster are shown in the MCL gene clusters 662 
table. The Pareto scaled graphs show the mean expression profiles of MCL clusters 1 (D), 2 663 
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(E), 3 (F), 4 (G), 5 (H), 6 (I), 7 (J), 8 (K), 9 (L) across all samples (n=23), including the 664 
samples in the TL and TNL groups. Samples are plotted on the x-axes. Genes with similar 665 
expression pattern across all samples are members of the same cluster. Each bar represents 666 
the average expression of all genes that cluster together in that sample. The error bar for each 667 
sample denotes the SD extrapolated from the expression of all cluster genes in that sample. 668 
PPROM n=5, PTL n=6, TL n=7, TNL n=5.  669 
 670 
Figure 4: Validation of microarray analysis. A, D, G, J: Tables show the fold-changes 671 
(FC) and adjusted p values (Adj.P.Val) across all comparisons for the 4 selected genes 672 
CEACAM3, PRAM1, FGD3 and NDRG2 as reported by FIOS genomics statistical analysis. 673 
qRT-PCR validated that CEACAM3 (B), PRAM1 (E) and FGD3 (H) were up-regulated, and 674 
NDRG2 (K) down-regulated in the PPROM group when compared to all other groups. Data 675 
analyzed using one-way ANOVA Dunnett’s test. qRT-PCR samples: PPROM n=5, PTL n=6, 676 
TL n=12, TNL n=5. Western blotting analysis confirmed that CEACAM3 (C) and FGD3 (I) 677 
were in higher concentration in the PPROM cervix compared to all other groups. PRAM1 (F) 678 
and NDRG2 (L) changes were also significant between PPROM and PTL/TL but not in TNL. 679 
Data analyzed using one-way ANOVA Dunnett’s test. Western blotting samples: PPROM 680 
n=4, PTL n=4, TL n=4, TNL n=4. Error bars denote ±SEM. *p<0.05, **p <0.01, 681 
***p<0.001. 682 
 683 
Figure 5: Localization of PRAM1 and CEACAM3 in the PPROM human cervix. 684 
PRAM1 and CEACAM3 positive cells were identified at the cervical stroma. PRAM1 was 685 
localized to the cytoplasm and CEACAM3 to the membrane of cells. CEACAM3 (B) and 686 
PRAM1 (C) did not co-localize (D). Double staining for PRAM1 (F) and CD45 (G) 687 
identified double positive population (H). PRAM1 cells (I), did not co-localize (K) with the 688 
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macrophage marker CD68 (J). PRAM1 cells (M) did not co-localize (O) with neutrophil 689 
Elastase (N). All scale bars 50 µm. Images representative of n=4.  690 
 691 
Figure 6: Localization of FGD3 and NDRG2 in the human cervix. Marginal NDRG2 692 
staining (C) was detected to the nuclei of endocervical epithelial cells stained positive for 693 
AE1/AE3 (D). D: NDRG2 staining was evidently stronger in cells surrounding blood vessels 694 
(indicated with asterisks). A co-staining for vWF (J; an endothelial cell marker) and NDRG2 695 
(K) confirmed that NDRG2 is localized to the cytoplasm of myofibroblasts surrounding 696 
blood vessels (L). NDRG2 was also localized to the cytoplasm of endocervical glandular 697 
cells (G) as was evident by co-localization (H) with AE1/AE3 (F). FGD3 was expressed 698 
solely in the cytoplasm of myofibroblasts (O) and co-localized with NDRG2 (T). Scale bars 699 
50 µm/ 100 µm as shown in each picture. Images representative of n=4. A-L: PTL cervix, M-700 
P: PPROM cervix, Q-T: TL cervix. vWF: Von Willebrand factor, AE1/AE3: Pan 701 
Cytokeratin.  702 
 703 
Figure 7: MMP-2 and MMP-9 activity in the human cervix. Gelatin zymography was 704 
performed on protein extracted from the cervix of women with PPROM (n=4), PTL (n=4), 705 
TL (n=4) and TNL (n=4). A: The activity of MMP-9 (82 kDa) was significantly higher in the 706 
PPROM cervix when compared to the other groups (*p=0.05, ***p=0.001 comparison). B: 707 
The activity of MMP-2 was similar in PPROM, PTL and TL but significantly lower in TNL 708 
when compared to the other groups (****p<0.0001). Data analyzed using one-way ANOVA 709 
Tukey’s test.  710 
 711 
 712 
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